-
With the recent Food and Drug Administration approval of Quartette, a new extended regimen oral contraceptive (OC) from Teva Pharmaceuticals of North Wales, PA, providers have more options to present to women considering this form of birth control.
-
While teen pregnancies are declining in the United States, the nation still leads the worlds high-income countries in live teen births, points out a recent Centers for Disease Control and Prevention (CDC) Public Health Grand Rounds session.1
-
What if multipurpose prevention technology (MPT) could prevent women from unintended pregnancy and sexually transmitted infections?
-
Clinicians who are members of the Washington, DC-based Association of Reproductive Health Professionals (ARHP) can take advantage of a unique new service, ARHPedia. ARHPedia connects healthcare providers to pharmaceutical resources through a comprehensive and convenient portal.
-
Implementation of the Patient Protection and Affordable Care Act of 2010 (ACA) will be an ongoing process, but one major change that already has begun is the expansion of community health centers (CHCs).
-
Young people between ages 13-24 represent more than a quarter of new HIV infections each year, and 60% of youth living with HIV are unaware they are infected, according to a new report from the Centers for Disease Control and Prevention (CDC).
-
Combined oral contraceptives should be sold over the counter in drugstores without a providers prescription, according to a new committee opinion issued by the American College of Obstetricians and Gynecologists (ACOG).
-
Check your clinics patient files for the last year. How many visits were made by males? According to 2010 data from the Agency for Healthcare Research and Quality, just over half of U.S. men (57%) see a doctor, nurse practitioner, or physician assistant for routine care, compared to nearly three-quarters (74%) of women.
-
Add new research to your clinics protocols: The risk of developing pelvic inflammatory disease (PID) following insertion of an intrauterine device (IUD) is very low, whether or not women have been screened beforehand for gonorrhea and chlamydia.
-
Calcium supplementation in women; type 2 diabetes treatments and pancreatitis risk; treating chronic idiopathic urticaria; rivaroxaban and VTE; and FDA actions.
